Abstract. Transforming growth factor ß (TGF-ß) signaling can inhibit tumor growth in developing tumors. However, it promotes tumor invasiveness and metastasis in late-stage tumors. A number of TGF-ß gene polymorphisms have been identified that can affect the survival of patients with advanced non-small cell lung cancer (NSCLC). In this study, we investigated the association of the TGF-ß1 polymorphism, C-509T, with survival in patients with advanced NSCLC. Japanese patients who were treated for unresectable advanced NSCLC between April 2003 and March 2008 at Kyoto University Hospital, were enrolled in this study. Analyses of genotype associations with survival outcomes were performed using statistical tests. The median survival of patients with the TT genotype was shorter, although not significantly, than that of patients with either the CT or CC genotype. Based on both univariable and multivariable analyses, the TGF-ß1 polymorphism, C-509T, was not associated with prognosis. In patients with a smoking status of <40 pack-years, the median survival was significantly shorter with the TT genotype than with the CT or CC genotype. Based on univariable analysis, stage IV cancer and the TT genotype had a significant prognostic effect on survival. Based on multivariable analysis, the TT genotype was a significantly independent prognostic factor for survival. There was no association between the TGF-ß1 polymorphism, C-509T, and survival in patients with advanced NSCLC. In patients with a smoking status of <40 pack-years, however, the TGF-ß1 polymorphism, C-509T, was significantly associated with the prognosis of advanced NSCLC, and the TT genotype was an independent prognostic factor for poor survival.
Introduction
The transforming growth factor ß1 (TGF-ß1) belongs to a superfamily of structurally related polypeptides that also includes TGF-ß2 and -ß3, activins, nodals and bone morphogenetic proteins (1, 2) . Alterations in TGF-ß signaling have been linked to a variety of human diseases, including cancer and inflammation. TGF-ß signaling plays a biphasic role in carcinogenesis. During the early phase of cancer development, TGF-ß acts as a tumor suppressor by inhibiting cellular proliferation and thus promoting cellular differentiation or apoptosis (3) (4) (5) . However, TGF-ß functions as a tumor promoter in the later stages of carcinogenesis. In cancer cells in which the suppressive functions of TGF-ß signaling have been overridden, TGF-ß induces cellular changes which are associated at least in part, with invasion and metastasis as a result of the stimulation of angiogenesis, suppression of the immune system and increased interaction of cancer cells with the extracellular matrix (3) (4) (5) .
Many polymorphisms have been identified in the TGF-ß1 gene (6) (7) (8) , and some of these variants have been associated with variations in TGF-ß1 levels. Some studies have reported on the association between lung cancer and TGF-ß1 polymorphisms (9, 10) , but none have reported on the association between these polymorphisms and lung cancer survival. A C to T base exchange located 509 bp from the first major transcription initiation site, has been linked to promoter activity enhancement. The T allele of the TGF-ß1 promoter polymorphism, C-509T, has been associated with increased serum levels of TGF-ß1 (11) . We therefore investigated the association of the TGF-ß1 polymorphism, C-509T, with survival in patients with advanced non-small cell lung cancer (NSCLC). Genotyping. Blood samples were collected from all patients at the time of recruitment. DNA was extracted from blood samples using a QIAamp DNA extraction kit (Qiagen, Tokyo, Japan). The TGF-ß1 polymorphism, C-509T (rs1800469), was genotyped using the 5'-nuclease assay (TaqMan) with the ABI prism 7300 Sequence Detecting System (Applied Biosystems, Foster City, CA, USA).
Materials and methods

Patients
Statistical analysis. The univariate relationships between each independent variable were examined using the ¯2 test or Fisher's exact test. In order to evaluate risk factors associated with prognosis, a Cox proportional hazards regression model with a step-down procedure, was used. Proportional hazard assumptions were checked and satisfied. Only those variables with P-values of <0.20 by univariable analysis were used for multivariable analysis. The associations between the TGF-ß1 polymorphism status and survival were estimated using the Kaplan-Meier method and were assessed using the log-rank test. All tests were two-tailed and P-values of <0.05 were considered to be statistically significant. All preceding statistical analyses were performed using JMP 8 software (SAS Institute, Cary, NC, USA).
Results
Patient clinical characteristics are summarized in Table I . This study included only a small subset of patients (132), due to the fact that patient selection was carried out according to Table I . Patient clinical characteristics (n=132). Table II . Association between the TGF-ß1 C-509T genotype and patient clinical characteristics. 
willingness to particpate. All patients were Japanese, including 89 males (67%) and 43 females (33%), with a median age of 67 years (range, 35-86 years). The number of dominant adenocarcinomas was 99 (75%). Approximately half the patients (64, 48%) were heavy smokers (≥40 pack-years). Fourteen (11%) patients had the Eastern Cooperative Oncology Group performance status (PS) of 2-4, while all the others had a good PS. Regarding the TGF-ß1 polymorphism, C-509T, 32 (24%) patients had the CC genotype, 62 (47%) had the CT genotype and 38 (29%) had the TT genotype. This ratio was similar to previous reports of healthy Japanese individuals (13, 14) . As summarized in Table II , no correlations existed between genotypes and clinical factors.
The median survival of patients with the TT genotype was shorter, although not significantly, than that of patients with either the CT or CC genotype (log-rank test, P=0.144) (Fig. 1) . A Cox regression analysis was performed on the 132 patients in order to determine the correlation between patient prognosis and clinical factors, including age (<70 vs. ≥70 years), gender (female vs. male), smoking status (<40 vs. ≥40 pack-years), histological type (adenocarcinoma vs. other), PS (0-1 vs. 2-4), stage (IIIA or IIIB vs. IV) and the TGF-ß1 polymorphism, C-509T (CC or CT vs. TT), (Table III) . Among these factors, a poor PS [hazard ratio (HR), 2.411; 95% confidence interval (CI), 1.234-4.322] had a significant prognostic effect on survival. Based on the multivariable analyses of gender, smoking status, PS, stage and the TGF-ß1 polymorphism, C-509T, a poor PS (HR, 2.183; 95% CI, 1.100-3.996; P=0.00270) was a significantly independent prognostic factor for survival (Table IV) .
It is known that cigarette smoking has an enormous influence on TGF-ß signaling (15, 16) . In order to prevent such an influence, we excluded heavy smokers from the analysis and focused on a smoking status of <40 pack-years (n=68). Patient clinical characteristics are summarized in Table I . Regarding the TGF-ß1 polymorphism, C-509T, 17 (25%) patients had the CC genotype, 32 (47%) had the CT genotype, and 19 (28%) had the TT genotype. No correlations were observed between the genotypes and clinical factors for any patient (Table V) . In contrast, the median survival of patients with the TT genotype was significantly shorter than that of patients with either the CT or CC genotype (log-rank test, P=0.0084) (Fig. 2) . In heavy smokers (≥40 pack-years; n=64), however, there was no significant difference in survival (log-rank test, P=0.38) (Fig. 3) . A Cox regression analysis was performed on the 68 patients who smoked for <40 years in order to determine the correlation between patient prognosis and the clinical factors mentioned above (Table VI) . Among these factors, stage IV cancer (HR, 2.069; 95% CI, 1.031-4.744; P=0.0401) and the TT genotype (HR, 2.127; 95% CI, 1.172-3.727; P=0.0141) had significant prognostic effects on survival. Based on the multivariable analyses of histological type, stage and the TGF-ß1 polymorphism, C-509T, the TT genotype (HR, 2.201; 95% CI, Table III . Univariable analysis of survival. 
-----------------------------------------------------------------------------------------------------Variables HR 95% CI P-values -----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------
a Statistically significant in Cox proportional hazard model analysis; P<0.05. Table IV . Multivariable analysis of survival. 
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1.212-3.864; P=0.0106) was a significantly independent prognostic factor for survival (Table VII) . PS could not be analyzed as the numbers were too small.
Discussion
This study shows no association between the TGF-ß1 polymorphism, C-509T, and survival in patients with advanced NSCLC. In patients with a smoking status of <40 pack-years, however, the TGF-ß1 polymorphism, C-509T, was significantly associated with the prognosis of advanced NSCLC, and the TT genotype was a poor independent prognostic factor for survival. To the best of our knowledge, this is the first study on the association between TGF-ß1 polymorphisms and survival in patients with advanced NSCLC. Comparison of survival time between patients with the TT genotype (n=19) and those with the CT or CC genotypes (n=45), focusing on patients with a smoking status of ≥40 pack-years. There was no significant difference between these two groups (log-rank test, P=0.38). Table V . Association between the TGF-ß1 C-509T genotype and clinical characteristics of patients with a smoking status of <40 pack-years, ------------------------------------------------ 
TGF-ß signaling can inhibit tumor growth in developing tumors. However, in late-stage tumors, the very same pathway promotes tumor invasiveness and metastasis (17) . Disruption of TGF-ß homeostasis occurs in several human cancers (3) (4) (5) . Data from both experimental model systems and studies of human cancers have clearly shown that not only the ligand itself but also its downstream elements, are important in suppressing primary tumorigenesis in many tissue types (18) . However, many human cancers, including lung cancer, often overexpress TGF-ß. Furthermore, TGF-ß enhances the invasiveness and metastatic potential of certain late-stage tumors (19) . This tumor-promoting effect is supported by the elevated levels of TGF-ß found in patients during the later stages of cancer, with its increased production being associated with increased invasiveness and poor prognosis in these patients (20) (21) (22) . The role of TGF-ß in cancer progression and metastasis is generally accompanied by decreased or altered TGF-ß responsiveness and the increased expression or activation of the TGF-ß ligand (19) . The loss of the TGF-ß response, which results in a lower inhibitory effect of TGF-ß on proliferation, has been associated with tumor development and/or tumor progression in many types of cancer (23, 24) .
Although this was a small, retrospective study focused on patients with a smoking status of <40 pack-years, this study shows that the TGF-ß1 polymorphism, C-509T, is significantly associated with prognosis in patients with advanced NSCLC and that the TT genotype is an independent prognostic factor for poor survival. Although TGF-ß1 serum levels were not evaluated in this study, the results are reasonable as the T allele of the TGF-ß1 polymorphism, C-509T, is associated with increased serum levels of TGF-ß1 (11) , and TGF-ß promotes tumor invasiveness and metastasis in late-stage tumors. On the contrary, the TGF-ß1 polymorphism, C-509T, was not associated with prognosis in heavy smokers. It is well known that cigarette smoking induces the activation of TGF-ß (15, 16) . Therefore, these results suggest that cigarette smoking has a greater influence on TGF-ß1 than the TGF-ß1 polymorphism, C-509T. However, many other TGF-ß1 poly-morphisms are also known to exist, and therefore larger studies are required in order to confirm the association between TGF-ß1 polymorphisms and tumor development or prognosis. Recently, inhibitors of TGF-ß signaling were developed for use in cancer treatments (17) . The results from this study suggest that such treatments could be effective for certain patients with advanced NSCLC. Table VI . Univariable analysis of survival in patients with a smoking status of <40 pack-years. - Table VII . Multivariable analysis of survival in patients with a smoking status of <40 pack-years.
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